News and Updates

Improving Lives Breakthrough T1D’s Improving Lives program focuses on devices, insulins, adjunctive therapies, treatments for complications, and psychosocial interventions to improve the health and quality of life of people living with T1D. Adjunctive therapies and complications There was significant focus on GLP-1 receptor agonists (GLP-1RAs) and SGLT inhibitors (SGLTi) in reducing long-term complications and improving […]

J.J. Spaun’s diagnosis story highlights the importance of screening and monitoring for type 1 diabetes in people of all ages.

The Medical Affairs team is working to ensure the clinical adoption of forthcoming manufactured cell therapies.

This Clinical Trials Awareness Day, we’re exploring lessons from clinical trials and debunking clinical trials misconceptions.

Breakthrough T1D believes that novel cell therapies in the clinical pipeline will transform T1D management, and Project ACT is how we’re going to make them a reality.

Learn more about GLP-1 therapies and SGLT inhibitors, and how drugs like Ozempic may one day be able to help people with type 1 diabetes.

Katie Howell was diagnosed with type 1 diabetes last year at age 25. Now, she's the first DIAGNODE-3 trial participant in NYC.

Breakthrough T1D's new Medical Affairs unit will address the numerous challenges contributing to the slow adoption of groundbreaking T1D therapies.

Marjorie Lazarre has seen the life-changing outcomes of T1D research and is confident clinical trials are the path to cures.

DIAGNODE-3 is a phase 3 clinical trial of the disease-modifying therapy Diamyd® that aims to preserve insulin-producing beta cells.